Adjuvant chemotherapy could not bring survival benefit to HR-positive, HER2-negative, pT1b-c/N0–1/M0 invasive lobular carcinoma of the breast: a propensity score matching study based on SEER database | BMC Cancer | Full Text

Adjuvant chemotherapy could not bring survival benefit to HR-positive, HER2-negative, pT1b-c/N0–1/M0 invasive lobular carcinoma of the breast: a propensity score matching study based on SEER database | BMC Cancer | Full Text

Adjuvant chemotherapy could not bring survival benefit to HR-positive, HER2-negative, pT1b-c/N0–1/M0 invasive lobular carcinoma of the breast: a propensity score matching study based on SEER database

The benefit of adjuvant chemotherapy in invasive lobular carcinoma (ILC) is still unclear. The objective of the current study was to elucidate the effectiveness of adjuvant chemotherapy in hormone receptor (HR...

Authors:Guangfu Hu, Guangxia Hu, Chengjiao Zhang, Xiaoyan Lin, Ming Shan, Yanmin Yu, Yongwei Lu, Ruijie Niu, Hui Ye, Cheng Wang and Cheng Xu

Citation:BMC Cancer 2020 20:136

Content type:Research article

Published on: 21 February 2020

• ViewFull Text
 
• ViewPDF